| Budget Amount *help |
¥48,500,000 (Direct Cost: ¥48,500,000)
Fiscal Year 2009: ¥9,700,000 (Direct Cost: ¥9,700,000)
Fiscal Year 2008: ¥9,700,000 (Direct Cost: ¥9,700,000)
Fiscal Year 2007: ¥9,700,000 (Direct Cost: ¥9,700,000)
Fiscal Year 2006: ¥9,700,000 (Direct Cost: ¥9,700,000)
Fiscal Year 2005: ¥9,700,000 (Direct Cost: ¥9,700,000)
|
|---|
| Research Abstract |
Our previous studies suggested that immunological approaches to activate HTLV-I-specific T-cell response potentially induce prophylactic and therapeutic effects on ATL. In order to verify this notion and apply for bedside, we indicated that vaccination reduced proviral load in a rat model, and that a subpopulation of HTLV-I-carriers showed weak HTLV-I-specific T-cell response and elevated proviral load. Moreover, we discovered an innate immune-mediated mechanism suppressing HTLV-I expression in vivo.
|
